Study finds ocular surface disease in 31% on dupilumab for atopic dermatitis

A prospective cohort study using the BioDay registry examined ocular surface disease (OSD) in adult patients with moderate-to-severe atopic dermatitis treated with dupilumab, following them at baseline, week 4, and week 28. The study reported that OSD was present in 94.0% of patients at baseline, though only 60.0% had reported ocular symptoms, and that dupilumab-associated OSD developed in 30.7% of patients over 28 weeks despite ophthalmic medication use rising from 15.3% to 64.7%. Conjunctival impression cytology showed goblet cell numbers remained stable but low, while MUC5AC mucin production significantly decreased during treatment.

Most relevant for: Adult patients with moderate-to-severe atopic dermatitis being treated with dupilumab.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.